Jianyu Weng

Guangdong Academy of Medical Sciences — China

Medicine · Health Sciences

25h-index3.3kcitations172works4.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(57), Hematopoietic Stem Cell Transplantation(38), Chronic Myeloid Leukemia Treatments(31), Chronic Lymphocytic Leukemia Research(23), CAR-T cell therapy research(22)

Publications171 total

Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional “3 + 7” intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial
Trials·2025Open Access
Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases
Journal of Hematology & Oncology·2025· 5 citedOpen Access
Comparing the efficacy and safety of the ABC-14 regimen (Azacitidine, Venetoclax, and Chidamide) with traditional “3+7” intensive induction regimen or AB-14 regimen (Venetoclax Combined with Azacitidine) in newly diagnosed AML: Study protocol for a prospective, multicenter, randomized, open-label clinical trial
Blood·2025Open Access
Results of POLARIS-1, a global Phase 3 study (Part A): Olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)
Blood·2025Open Access
Plasmacytoid dendritic cells (PDCs) signatures from integrated profiling predict AML prognosis and treatment response
Blood·2025
The ABC-14 regimen (Azacitidine, Venetoclax, and Chidamide) as a bridge to allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia: A single-center experience
Blood·2025Open Access
Causal Effects of AL Amyloidosis on Autoimmune Diseases and the Role of Inflammatory Cytokines: Insights from Mendelian Randomization
2025Open Access
[Analysis of peripheral blood monocyte subsets in chronic myelomonocytic leukemia: a single-center study].
PubMed·2025
[Establishment and Mechanistic Study of Venetoclax-Resistant Cell Lines in Acute Myeloid Leukemia].
PubMed·2025
Reduced morbidity and mortality of cGVHD in patients who received treatment with mesenchymal stromal cells for steroid-resistant aGVHD: long-term follow-up of a randomized phase 3 trial
Experimental Hematology and Oncology·2025Open Access
Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia
Haematologica·2025· 3 citedOpen Access
Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study
Blood·2024· 2 citedOpen Access
Single-Cell Analysis Reveals Altered Tumor Microenvironments of Relapse/ Refractory and Remission-Associated Acute Myeloid Leukemia Treated By ABC-14 Regimen
Blood·2024Open Access
Olverembatinib 30 Mg <i> <i>Versus</i> </i> 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis
Blood·2024
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies
Journal of Hematology & Oncology·2024· 64 citedOpen Access
Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China
Blood·2024
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE
Annals of Hematology·2024· 7 citedOpen Access
Safety and efficacy of lisaftoclax, a novel BCL-2 inhibitor, in combination with azacitidine in patients with treatment-naïve or relapsed or refractory acute myeloid leukemia.
Journal of Clinical Oncology·2024· 2 cited
Outcomes of intermediate or high‐risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience
Clinical and Translational Science·2023· 1 citedOpen Access
Diagnostic and prognostic value of ferroptosis-related genes in patients with Myelodysplastic neoplasms
Hematology·2023· 4 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Xin Du(31), Peilong Lai(27), Suxia Geng(27), Xin Huang(16), Yangqiu Li(13), Zesheng Lu(12), Suijing Wu(10), Peng Li(10), Xin Du(9), Chengxin Deng(9), Minming Li(9), Duanqing Pei(8), Yulian Wang(8), Chenwei Luo(8), Shaohua Chen(8), Zhiwu Jiang(7), Ping Wu(7), Chang He(6), Lisi Huang(6), Lingji Zeng(6)